Bridgewater Associates LP Purchases 1,350 Shares of Thermo Fisher Scientific Inc (TMO)

Bridgewater Associates LP boosted its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 15.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,194 shares of the medical research company’s stock after purchasing an additional 1,350 shares during the quarter. Bridgewater Associates LP’s holdings in Thermo Fisher Scientific were worth $1,779,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. BB&T Securities LLC raised its position in shares of Thermo Fisher Scientific by 4.4% during the 1st quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares in the last quarter. Mitchell Capital Management Co. raised its position in shares of Thermo Fisher Scientific by 40.3% during the 2nd quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock worth $7,841,000 after buying an additional 12,910 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after buying an additional 5,213 shares in the last quarter. Toronto Dominion Bank raised its position in shares of Thermo Fisher Scientific by 53.5% during the 1st quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock worth $16,450,000 after buying an additional 37,307 shares in the last quarter. Finally, IBM Retirement Fund raised its position in shares of Thermo Fisher Scientific by 117.7% during the 2nd quarter. IBM Retirement Fund now owns 9,537 shares of the medical research company’s stock worth $1,860,000 after buying an additional 5,157 shares in the last quarter. Hedge funds and other institutional investors own 83.32% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/20/bridgewater-associates-lp-purchases-1350-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 192.44 on Friday. The stock has a market capitalization of $75.07 billion, a P/E ratio of 33.53 and a beta of 1.05. The stock has a 50 day moving average of $190.47 and a 200 day moving average of $176.29. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The business had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the company posted $2.03 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.

In related news, SVP Gregory J. Herrema sold 30,000 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total value of $5,280,600.00. Following the sale, the senior vice president now directly owns 67,016 shares in the company, valued at approximately $11,796,156.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director C Martin Harris sold 360 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares in the company, valued at $961,312.64. The disclosure for this sale can be found here. Insiders sold a total of 52,738 shares of company stock worth $9,302,112 over the last quarter. 0.49% of the stock is currently owned by corporate insiders.

A number of analysts have commented on the stock. Leerink Swann boosted their price target on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research report on Monday, October 9th. Jefferies Group LLC restated a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. Barclays PLC restated an “overweight” rating and set a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. Finally, Zacks Investment Research upgraded

A number of other large investors have also recently modified their holdings of the stock. BB&T Securities LLC raised its position in shares of Thermo Fisher Scientific by 4.4% during the 1st quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares in the last quarter. Mitchell Capital Management Co. raised its position in shares of Thermo Fisher Scientific by 40.3% during the 2nd quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock worth $7,841,000 after buying an additional 12,910 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after buying an additional 5,213 shares in the last quarter. Toronto Dominion Bank raised its position in shares of Thermo Fisher Scientific by 53.5% during the 1st quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock worth $16,450,000 after buying an additional 37,307 shares in the last quarter. Finally, IBM Retirement Fund raised its position in shares of Thermo Fisher Scientific by 117.7% during the 2nd quarter. IBM Retirement Fund now owns 9,537 shares of the medical research company’s stock worth $1,860,000 after buying an additional 5,157 shares in the last quarter. Hedge funds and other institutional investors own 83.32% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/20/bridgewater-associates-lp-purchases-1350-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 192.44 on Friday. The stock has a market capitalization of $75.07 billion, a P/E ratio of 33.53 and a beta of 1.05. The stock has a 50 day moving average of $190.47 and a 200 day moving average of $176.29. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The business had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the company posted $2.03 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.

In related news, SVP Gregory J. Herrema sold 30,000 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total value of $5,280,600.00. Following the sale, the senior vice president now directly owns 67,016 shares in the company, valued at approximately $11,796,156.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director C Martin Harris sold 360 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares in the company, valued at $961,312.64. The disclosure for this sale can be found here. Insiders sold a total of 52,738 shares of company stock worth $9,302,112 over the last quarter. 0.49% of the stock is currently owned by corporate insiders.

A number of analysts have commented on the stock. Leerink Swann boosted their price target on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research report on Monday, October 9th. Jefferies Group LLC restated a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. Barclays PLC restated an “overweight” rating and set a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. Finally, Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price target on the stock in a research report on Thursday, September 21st. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $203.64.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply